VXRT * Stock Overview
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Vaxart, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.00 |
| 52 Week High | US$23.00 |
| 52 Week Low | US$10.00 |
| Beta | 0.70 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -92.66% |
| 5 Year Change | n/a |
| Change since IPO | -92.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| VXRT * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | -20.0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how VXRT * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how VXRT * performed against the MX Market.
Price Volatility
| VXRT * volatility | |
|---|---|
| VXRT * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: VXRT *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine VXRT *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 109 | Steven Lo | vaxart.com |
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Vaxart, Inc. Fundamentals Summary
| VXRT * fundamental statistics | |
|---|---|
| Market cap | Mex$2.88b |
| Earnings (TTM) | -Mex$1.49b |
| Revenue (TTM) | Mex$346.33m |
8.1x
P/S Ratio-1.9x
P/E RatioIs VXRT * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VXRT * income statement (TTM) | |
|---|---|
| Revenue | US$16.76m |
| Cost of Revenue | US$66.26m |
| Gross Profit | -US$49.50m |
| Other Expenses | US$22.83m |
| Earnings | -US$72.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | -295.37% |
| Net Profit Margin | -431.61% |
| Debt/Equity Ratio | 7.1% |
How did VXRT * perform over the long term?
See historical performance and comparison